Related Experiment Video
Updated: Aug 8, 2026
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
[Clinical analysis of 10 cases of true histiocytic lymphoma]
Insights
True histiocytic lymphoma is a rare non-Hodgkin's lymphoma (NHL). This study found it responds well to chemotherapy and irradiation, offering a favorable prognosis for patients.
Area of Science:
- Hematology
- Oncology
- Pathology
Context:
- True histiocytic lymphoma (THL) is an uncommon non-Hodgkin's lymphoma (NHL).
- Understanding THL's clinical and pathological features is crucial for diagnosis and treatment.
- Limited data exists on the characteristics and outcomes of THL.
Purpose:
- To investigate the clinical and pathological characteristics of true histiocytic lymphoma.
- To evaluate treatment response and survival rates in THL patients.
Summary:
- Retrospective review of 10 THL cases (1986-1996).
- THL represented 0.6% of NHL cases. All cases showed specific enzyme markers; 6 excluded lymphoid origin via immunohistochemistry.
- Treatment included chemotherapy, irradiation, and/or surgery, with one bone marrow transplant.
- Achieved 100% response rate, with 1, 3, and 5-year survival rates of 100%, 90%, and 70% respectively.
- Projected 10-year disease-free survival is 40%.
Impact:
- THL is a rare NHL subset with distinct characteristics.
- Lymph node-originating THL is sensitive to chemotherapy and irradiation.
- This study highlights a favorable prognosis for THL with appropriate treatment.
Objective:
To explore the clinical and pathological characteristics of true histiocytic lymphoma.
Methods:
The clinical and pathological data of 10 true histiocytic lymphoma patients admitted between 1986 and 1996 to our hospital was retrospectively reviewed.
Results:
True histiocytic lymphoma accounted for 0.6% of non-Hodgkin's lymphoma(NHL) admitted in this period to our hospital. Enzymes associated with true histiocytic lymphoma were detected in all the 10 cases. The tumor cells were excluded from T/B lymphoid origin in 6 cases by immunohistochemistry. Eight cases received chemotherapy + irradiation +/- excision of primary lesion, 1 simply received irradiation and 1 received bone marrow transplantation. The response rate was 100%, with a 1, 3 and 5 year survival rate of 100%, 90% and 70%, respectively. The expected 10 year disease free survival rate is 40%.
Conclusion:
True histiocytic lymphoma is a rare subset of NHL. Those originated from lymph node are sensitive to chemotherapy and irradiation with a favorable prognosis.
More Related Videos
07:52Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
Published on: January 9, 2019
09:08Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021